Buchumschlag

Long non-coding RNAs as a biomarker for homologous recombination deficiency and parp inhibitor sensitivity in high-grade serous ovarian cancers

Homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors are key determinants of therapeutic response in high-grade serous ovarian cancer (HGSC), yet predictive biomarkers beyond BRCA1/2 mutations or genomic HRD scores remain inadequate. Here, we investigate the potential of long...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Doberstein, Kai (Verfasst von) , Panther, Johannes (Verfasst von) , Hahnen, Eric (Verfasst von) , Richters, Lisa (Verfasst von) , Schouten, Philip (Verfasst von) , Harter, Philipp (Verfasst von) , Heitz, Florian (Verfasst von) , Kommoss, Stefan (Verfasst von) , Berlit, Sebastian (Verfasst von) , Tuschy, Benjamin (Verfasst von) , Sütterlin, Marc (Verfasst von) , Marmé, Frederik (Verfasst von)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 01 October 2025
In: Communications biology
Year: 2025, Jahrgang: 8, Pages: 1-17
ISSN:2399-3642
DOI:10.1038/s42003-025-08836-9
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s42003-025-08836-9
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s42003-025-08836-9
Volltext
Verfasserangaben:Kai Doberstein, Johannes Panther, Eric Hahnen, Lisa Richters, Philip C. Schouten, Philipp Harter, Florian Heitz, Stefan Kommoss, Sebastian Berlit, Benjamin Tuschy, Marc Sütterlin & Frederik Marmé
Beschreibung
Zusammenfassung:Homologous recombination deficiency (HRD) and sensitivity to PARP inhibitors are key determinants of therapeutic response in high-grade serous ovarian cancer (HGSC), yet predictive biomarkers beyond BRCA1/2 mutations or genomic HRD scores remain inadequate. Here, we investigate the potential of long non-coding RNAs (lncRNAs) as predictive markers of HRD and PARP inhibitor response. We identify a panel of lncRNAs that stratifies HGSC tumors by HRD status and drug sensitivity. Among these, ENSG00000272172.1 is significantly upregulated in HRD-positive tumors and is detectable in both formalin-fixed tissue and plasma, supporting its use as a minimally invasive biomarker. Functional analyses reveal that this lncRNA contributes to genome stability by modulating replication dynamics. These findings highlight a previously unrecognized role for lncRNAs in the HRD phenotype and suggest translational potential for ENSG00000272172.1 in guiding clinical decision-making.
Beschreibung:Gesehen am 18.12.2025
Beschreibung:Online Resource
ISSN:2399-3642
DOI:10.1038/s42003-025-08836-9

Ähnliche Einträge